REGN 9933
Alternative Names: REGN-9933Latest Information Update: 25 Dec 2024
Price :
$50 *
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antithrombotics; Monoclonal antibodies
- Mechanism of Action Factor XI inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Venous thromboembolism
- No development reported Thrombosis
Most Recent Events
- 19 Dec 2024 Adverse events and efficacy data from the phase-II ROXI-VTE-I trial in Venous thromboembolism released by Regeneron Pharmaceuticals ,
- 19 Dec 2024 Regeneron Pharmaceuticals plans a phase-III trial in 2025
- 28 Nov 2024 No recent reports of development identified for phase-I development in Thrombosis(In volunteers) in Belgium (IV)